The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

WITH all the buzz around the so-called ‘miracle’ weight-loss jabs Ozempic, you could easily mistake it for a cure for all. Although created to help manage type 2 diabetes the ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

“The FTC’s administrative action seeks to put an end to the Big Three PBMs’ exploitative conduct and marks an important step ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

Shares in Novo Nordisk (NYSE: NVO) fell more than 4% following the market open on Friday after the Danish pharma giant released data from a phase 2a clinical trial with its obesit ...

However, the analysts said: “Given our own forecast that CPI inflation will rise back to 2.9pc by January next year (perhaps ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...